keyword
MENU ▼
Read by QxMD icon Read
search

Breast cancer subtypes

keyword
https://www.readbyqxmd.com/read/29350329/detection-of-human-papillomavirus-dna-in-tumors-from-rwandese-breast-cancer-patients
#1
REVIEW
Thierry Habyarimana, Mohammed Attaleb, Jean Baptiste Mazarati, Youssef Bakri, Mohammed El Mzibri
BACKGROUND: During the last decades, a great interest was given to viral etiology of breast cancer. Indeed, due to recent technical improvements and some encouraging new results, it has been a resurgence of interest in the possibility that a substantial proportion of human breast cancers may be caused by viral infections. High-risk genotypes of human papillomavirus (HPV) have been found in breast cancer cases. In the present study, we aimed to assess the presence of HPV DNA in breast cancer cases from Rwanda and to evaluate the association between HPV infection and clinico-pathological features...
January 19, 2018: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/29349773/progestin-only-and-combined-oral-contraceptives-and-receptor-defined-premenopausal-breast-cancer-risk-the-norwegian-women-and-cancer-study
#2
Marit Busund, Nora S Bugge, Tonje Braaten, Marit Waaseth, Charlotta Rylander, Eiliv Lund
Receptor-defined subtypes of breast cancer represent distinct cancer types and have differences in risk factors. Whether the two main hormonal forms of oral contraceptives (OCs); i.e. progestin-only (POC) and combined oral contraceptives (COC), are differentially associated with these subtypes are not well known. The aim of this study was to assess the effect of POC and COC use on hormone receptor-defined breast cancer risk in premenopausal women in a prospective population-based cohort - The Norwegian Women and Cancer study (NOWAC)...
January 19, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29348905/bridging-the-divide-preclinical-research-discrepancies-between-triple-negative-breast-cancer-cell-lines-and-patient-tumors
#3
REVIEW
Andrew Sulaiman, Lisheng Wang
Triple-negative breast cancer (TNBC) is the most refractory subtype of breast cancer and disproportionately accounts for the majority of breast cancer related deaths. Effective treatment of this disease remains an unmet medical need. Over the past several decades, TNBC cell lines have been used as the foundation for drug development and disease modeling. However, ever-mounting research demonstrates striking differences between cell lines and clinical TNBC tumors, disconnecting bench research and actual clinical responses...
December 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/29348858/the-survival-benefit-of-neoadjuvant-chemotherapy-and-pcr-among-patients-with-advanced-stage-triple-negative-breast-cancer
#4
Tithi Biswas, Jimmy T Efird, Shreya Prasad, Charulata Jindal, Paul R Walker
Triple negative breast cancer (TNBC) is an aggressive subtype that accounts for 15-20% of cases, with a higher incidence of relapse/death. Even with adjuvant chemotherapy, the 5 year distant metastasis-free survival rate remains low. A total of 452 tumor registry patients with TNBC and no evidence of metastatic disease were identified over the period of 1996-2011. The median age and follow-up time were 51 (range=21-88) and 3.9 (range=0.14-14) years. Approximately 75% of patients with stage III disease received neoadjuvant chemotherapy (NACT) compared with 47% for stage II...
December 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/29348684/mithramycin-a-suppresses-basal-triple-negative-breast-cancer-cell-survival-partially-via-down-regulating-kr%C3%A3-ppel-like-factor-5-transcription-by-sp1
#5
Rong Liu, Xu Zhi, Zhongmei Zhou, Hailin Zhang, Runxiang Yang, Tianning Zou, Ceshi Chen
As the most malignant breast cancer subtype, triple-negative breast cancer (TNBC) does not have effective targeted therapies clinically to date. As a selective Sp1 inhibitor, Mithramycin A (MIT) has been reported to have anti-tumor activities in multiple cancers. However, the efficacy and the mechanism of MIT in breast cancer, especially TNBC, have not been studied. In this study, we demonstrated that MIT suppressed breast cancer cell survival in a dosage-dependent manner. Interestingly, TNBC cells were more sensitive to MIT than non-TNBC cells...
January 18, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29348460/fyn-promotes-mesenchymal-phenotypes-of-basal-type-breast-cancer-cells-through-stat5-notch2-signaling-node
#6
Ga-Hang Lee, Ki-Chun Yoo, Yoojeong An, Hae-June Lee, Minyoung Lee, Nizam Uddin, Min-Jung Kim, In-Gyu Kim, Yongjoon Suh, Su-Jae Lee
Basal type breast cancer is the most aggressive and has mesenchymal features with a high metastatic ability. However, the signaling node that determines the basal type features in breast cancer remains obscure. Here, we report that FYN among SRC family kinases is required for the maintenance of basal type breast cancer subtype. Importantly, FYN enhanced NOTCH2 activation in basal type breast cancer cells through STAT5-mediated upregulation of Jagged-1 and DLL4 NOTCH ligands, thereby contributed to mesenchymal phenotypes...
January 19, 2018: Oncogene
https://www.readbyqxmd.com/read/29346386/histological-subtypes-of-mouse-mammary-tumors-reveal-conserved-relationships-to-human-cancers
#7
Daniel P Hollern, Matthew R Swiatnicki, Eran R Andrechek
Human breast cancer has been characterized by extensive transcriptional heterogeneity, with dominant patterns reflected in the intrinsic subtypes. Mouse models of breast cancer also have heterogeneous transcriptomes and we noted that specific histological subtypes were associated with particular subsets. We hypothesized that unique sets of genes define each tumor histological type across mouse models of breast cancer. Using mouse models that contained both gene expression data and expert pathologist classification of tumor histology on a sample by sample basis, we predicted and validated gene expression signatures for Papillary, EMT, Microacinar and other histological subtypes...
January 2018: PLoS Genetics
https://www.readbyqxmd.com/read/29345443/suv-calculation-in-breast-cancer-which-normalization-should-be-applied-when-using-18f-fdg-pet
#8
Olivier Humbert, Jean-Marc Riedinger, David Chardin, Isabelle Desmoulins, François Brunotte, Alexandre Cochet
BACKGROUND: When using 18F-FDG PET, glucose metabolism quantification is affected by various factors. We aimed to investigate the benefit of different SUV normalizations to improve the accuracy of 18F-FDG uptake to predict breast cancer aggressiveness and response to treatment. METHODS: Two hundred fifty-two women with locally advanced breast cancer treated with neoadjuvant chemotherapy (NAC) were included. Women underwent 18F-FDG PET before and after the first course of NAC...
January 17, 2018: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29345290/role-of-nestin-expression-in-angiogenesis-and-breast-cancer-progression
#9
Aleksandra Nowak, Jędrzej Grzegrzółka, Alicja Kmiecik, Aleksandra Piotrowska, Rafał Matkowski, Piotr Dzięgiel
Nestin is an intermediate filament protein and a stem cell marker expressed in several tumours. There is growing evidence of an association between the expression level of nestin and the pathogenesis of triple-negative breast cancer (TNBC). Nestin is also expressed in newly forming tumour vessels and is a valuable marker of ongoing angiogenesis. In this study, we aimed to evaluate the prognostic value of nestin expression in breast tumour cells and to determine whether this expression influences angiogenesis...
February 2018: International Journal of Oncology
https://www.readbyqxmd.com/read/29344885/microrna-networks-in-breast-cancer-cells
#10
Andliena Tahiri, Miriam R Aure, Vessela N Kristensen
A variety of molecular techniques can be used in order to unravel the molecular composition of cells. In particular, the microarray technology has been used to identify novel biomarkers that may be useful in the diagnosis, prognosis, or treatment of cancer. The microarray technology is ideal for biomarker discovery as it allows for the screening of a large number of molecules at once. In this review, we focus on microRNAs (miRNAs) which are key molecules in cells and regulate gene expression post-transcriptionally...
2018: Methods in Molecular Biology
https://www.readbyqxmd.com/read/29344857/adaptation-of-laser-microdissection-technique-to-nanostring-rna-analysis-in-the-study-of-a-spontaneous-metastatic-mammary-carcinoma-mouse-model
#11
Nadia P Castro, Yelena G Golubeva
The mouse model characterized by spontaneous lung metastasis from JygMC (A) cells closely resembles the human triple negative breast cancer (TNBC) subtype. The primary tumors morphologically present both epithelial and spindle-like cells, but metastases in lung parenchyma display only adenocarcinoma properties. In the study of molecular signatures, laser capture microdissection (LCM) on frozen tissue sections was used to separate the following regions of interest: the epithelial-mesenchymal transition (EMT), mesenchymal-epithelial transition (MET), carcinoma, lung metastases, normal mammary gland and normal lung parenchyma...
2018: Methods in Molecular Biology
https://www.readbyqxmd.com/read/29344641/inhibition-of-rptor-overcomes-resistance-to-egfr-inhibition-in-triple-negative-breast-cancer-cells
#12
Kyu Sic You, Yong Weon Yi, Sahng-June Kwak, Yeon-Sun Seong
Triple-negative breast cancer (TNBC) cells frequently exhibit activated growth factor signaling and resistance to inhibitors for epidermal growth factor receptor (EGFR), despite the overexpression of EGFR protein, and this is associated with a malignant behavior and a poor prognosis. In this study, to elucidate the underlying mechanisms of resistance to EGFR inhibitor and identify inhibitors that exert a synergistic effect with EGFR inhibition, we examined the inhibitory effects of selected protein kinase inhibitors (PKIs) in combination with gefitinib on the viability of a mesenchymal stem-like (MSL) subtype TNBC cell line...
January 15, 2018: International Journal of Oncology
https://www.readbyqxmd.com/read/29344276/the-clinicopathological-features-and-survival-outcomes-of-different-histological-subtypes-in-triple-negative-breast-cancer
#13
Hong-Ye Liao, Wen-Wen Zhang, Jia-Yuan Sun, Feng-Yan Li, Zhen-Yu He, San-Gang Wu
Purpose: To determine the clinicopathological features and survival outcomes of triple-negative breast cancer (TNBC) according to different histological subtypes. Methods: Using the Surveillance, Epidemiology, and End Results database, we included TNBC cases in 2010-2013. The effect of histological subtype on breast cancer-specific survival (BCSS) and overall survival (OS) were analyzed using univariate and multivariate analyses. Results: A total of 19,900 patients were identified. Infiltrating ductal carcinoma not otherwise specified accounted for 91...
2018: Journal of Cancer
https://www.readbyqxmd.com/read/29344265/high-expression-of-pu-1-is-associated-with-her-2-and-shorter-survival-in-patients-with-breast-cancer
#14
Jing Lin, Wei Liu, Tian Luan, Lili Yuan, Wei Jiang, Huilong Cai, Weiguang Yuan, Yuwen Wang, Qingyuan Zhang, Lihong Wang
The transcription factor PU.1 was previously identified as an oncogene or a tumor suppressor in different types of leukemia. The aim of the present study was to investigate the expression of PU.1 in breast cancer and to analyze its association with clinical features and prognosis. Immunohistochemistry was used to determine PU.1 expression in breast cancer tissue microarrays and paraffin-embedded sections. The association between PU.1 expression and clinicopathological factors was assessed by using chi-square test...
December 2017: Oncology Letters
https://www.readbyqxmd.com/read/29344162/effects-of-rat-bone-marrow-derived-mesenchymal-stem-cells-on-breast-cancer-cells-with-differing-hormone-receptor-status
#15
Ying Wang, Shan Shao, Minna Luo, Shangke Huang, Lu Feng, Na Yuan, Fang Wu, Chengxue Dang, Xinhan Zhao
Breast cancer is a heterogeneous disease that can be classified into several molecular intrinsic subtypes according to hormone markers, including estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2. Breast cancer cases with different hormone status vary with respect to patient morbidity, metastasis organotropism and disease progression. It is well known that the most preferential relapse site of breast cancer is in the bone, but the metastatic incidence is markedly higher in hormone receptor-positive cancer compared with that in hormone receptor-negative cancers...
December 2017: Oncology Letters
https://www.readbyqxmd.com/read/29342219/the-expression-profile-and-prognostic-significance-of-eukaryotic-translation-elongation-factors-in-different-cancers
#16
Md Khurshidul Hassan, Dinesh Kumar, Monali Naik, Manjusha Dixit
Eukaryotic translation factors, especially initiation factors have garnered much attention with regards to their role in the onset and progression of different cancers. However, the expression levels and prognostic significance of translation elongation factors remain poorly explored in different cancers. In this study, we have investigated the mRNA transcript levels of seven translation elongation factors in different cancer types using Oncomine and TCGA databases. Furthermore, we have identified the prognostic significance of these factors using Kaplan-Meier Plotter and SurvExpress databases...
2018: PloS One
https://www.readbyqxmd.com/read/29341157/minimizing-inequality-in-access-to-precision-medicine-in-breast-cancer-by-real-time-population-based-molecular-analysis-in-the-scan-b-initiative
#17
L Rydén, N Loman, C Larsson, C Hegardt, J Vallon-Christersson, M Malmberg, H Lindman, A Ehinger, L H Saal, Å Borg
BACKGROUND: Selection of systemic therapy for primary breast cancer is currently based on clinical biomarkers along with stage. Novel genomic tests are continuously being introduced as more precise tools for guidance of therapy, although they are often developed for specific patient subgroups. The Sweden Cancerome Analysis Network - Breast (SCAN-B) initiative aims to include all patients with breast cancer for tumour genomic analysis, and to deliver molecular subtype and mutational data back to the treating physician...
January 2018: British Journal of Surgery
https://www.readbyqxmd.com/read/29340880/gata-3-is-superior-to-gcdfp-15-and-mammaglobin-to-identify-primary-and-metastatic-breast-cancer
#18
Yun-Bi Ni, Julia Y S Tsang, Mu-Min Shao, Siu-Ki Chan, Sai-Yin Cheung, Joanna Tong, Ka-Fai To, Gary M Tse
PURPOSE: Despite numerous studies on the utility of GATA-3 as breast cancer marker, its comparison with other breast markers, its concordance between primary and metastatic tumors and its expression in primary cancers from sites with frequent breast metastases remains unclear. METHODS: To address these questions, totally 993 invasive breast cancers (IBC), 254 paired nodal metastases, 23 distant metastases, and 208 lung carcinomas were included. GATA-3 expression was analyzed by immunohistochemistry and compared to other breast markers [gross cystic disease fluid protein 15 (GCDFP-15) and mammaglobin (MGB)]...
January 16, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29340027/dual-sirt1-expression-patterns-strongly-suggests-its-bivalent-role-in-human-breast-cancer
#19
Khaldoun Rifaï, Gaëlle Judes, Mouhamed Idrissou, Marine Daures, Yves-Jean Bignon, Frédérique Penault-Llorca, Dominique Bernard-Gallon
Breast cancer is the most common cancer in women, and the leading cause of cancer death in women worldwide. SIRT1 (silent mating type information regulation 2 homolog) 1 is a class-III histone deacetylase involved in apoptosis regulation, DNA repair and tumorigenesis. However, its role in breast carcinoma remains controversial, as both tumor-suppressive and tumor-promoting functions have been reported. Also, there are very few reports available where expression of SIRT1 is comprehensively analyzed in breast tumors classified by molecular subtype...
December 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29339815/mcl-1-is-a-prognostic-indicator-and-drug-target-in-breast-cancer
#20
Kirsteen J Campbell, Sandeep Dhayade, Nicola Ferrari, Andrew H Sims, Emma Johnson, Susan M Mason, Ashley Dickson, Kevin M Ryan, Gabriela Kalna, Joanne Edwards, Stephen G W Tait, Karen Blyth
Analysis of publicly available genomic and gene expression data demonstrates that MCL1 expression is frequently elevated in breast cancer. Distinct from other pro-survival Bcl-2 family members, the short half-life of MCL-1 protein led us to investigate MCL-1 protein expression in a breast cancer tissue microarray and correlate this with clinical data. Here, we report associations between high MCL-1 and poor prognosis in specific subtypes of breast cancer including triple-negative breast cancer, an aggressive form that lacks targeted treatment options...
January 16, 2018: Cell Death & Disease
keyword
keyword
38739
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"